Stay up to date

News

see all news
New data from Proclarix together with Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis to be showcased at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

February 11, 2020

Proteomedix appoints Helge Lubenow as new CEO

January 10, 2020

Publications

see all publications
Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.

Steuber T, Tennstedt P, Macagno A, Athanasiou A, Wittig A, Huber R, Golding B, Schiess R, Gillessen S. BJU Int. 2018 Sep 14. doi: 10.1111/bju.14540. PMID: 30216634

Thrombospondin 1 and cathepsin D improve the detection of high-grade prostate cancer and reduce the number of unnecessary prostate biopsies

Klocker H, Steiner E, Horninger W, Thomas S, Tennstedt P, Macagno A, Athanasiou A, Wittig A, Huber R, Schiess R, Gillessen S. 33rd Annual EAU Congress, 16-20 March 2018, Copenhagen, Denmark

Events

see all events
AACC Annual Meeting

July 29 - August 2, Chicago, US

DGU congress

September 26-29, in Dresden, Germany